WALTHAM, Mass., May 21, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the US and Canada), to evaluate DF9001, Dragonfly's EGFR immune engager, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors expressing EGFR..

马萨诸塞州沃尔瑟姆，2024年5月21日/PRNewswire/--蜻蜓治疗公司（Dragonfly Therapeutics，Inc.）是一家开发新型免疫疗法的临床阶段生物技术公司，今天宣布，它已与默克（Merck）（在美国和加拿大以外称为MSD）进行临床合作，以评估蜻蜓的EGFR免疫参与者DF9001与默克的抗PD-1疗法KEYTRUDA®（pembrolizumab）联合用于表达EGFR的晚期实体瘤患者。。

'Merck, a trusted leader in drug development, has been a wonderful collaborator with Dragonfly since we signed our first collaboration agreement in 2018,' said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. 'We are pleased to enter into this agreement with Merck for our ongoing, investigational Phase 1 trial of DF9001.

Dragonfly Therapeutics联合创始人兼首席执行官比尔·哈尼（BillHaney）说：“自2018年我们签署第一份合作协议以来，默克公司是药物开发领域值得信赖的领导者，一直是Dragonfly的出色合作者。”我们很高兴与默克公司就我们正在进行的DF9001研究性第一阶段试验达成协议。

In preclinical models, DF9001 engages multiple immune effector cells to drive anti-tumor activity and induces PD-L1 expression in tumor cells, sensitizing cold tumors to checkpoint inhibitors. We are hopeful that DF9001 in combination with KEYTRUDA will drive potent anti-tumor activity in a broad range of indications and are excited to further accelerate progress in the clinic to benefit patients in need.'.

在临床前模型中，DF9001参与多种免疫效应细胞以驱动抗肿瘤活性并诱导肿瘤细胞中的PD-L1表达，使冷肿瘤对检查点抑制剂敏感。我们希望DF9001与KEYTRUDA的结合将在广泛的适应症中推动有效的抗肿瘤活性，并很高兴进一步加速临床进展，使有需要的患者受益。”。

Dragonfly is the study sponsor and first patients are expected to receive DF9001 in combination with pembrolizumab in Q4 2024. Clinical trial sites are currently open for monotherapy dosing in the U.S., with additional sites in North America and Europe expected to open in 2024. Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT 05597839)..

蜻蜓是研究赞助商，预计首批患者将于2024年第4季度接受DF9001联合pembrolizumab治疗。临床试验地点目前在美国开放单药治疗剂量，北美和欧洲的其他地点预计将于2024年开放。有关试验的其他信息，包括资格标准，请访问：https://clinicaltrials.gov（ClinicalTrials.gov标识符：NCT 05597839）。。

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

KEYTRUDA® 是美国新泽西州拉威市默克公司股份有限公司子公司默克夏普多姆有限责任公司的注册商标。

About DF9001

关于DF9001

DF9001 is an investigational first-in-class multi-specific drug candidate that targets EGFR and potently redirects natural killer (NK) cells, gamma-delta T cells, and CD8 T cells by engaging activating receptors NKG2D and CD16. DF9001 was discovered and developed using Dragonfly's TriNKET® platform.

DF9001是一种研究性的一流多特异性候选药物，可靶向EGFR，并通过激活受体NKG2D和CD16有效重定向自然杀伤（NK）细胞，γδT细胞和CD8 T细胞。DF9001是使用蜻蜓的TriNKET®平台发现和开发的。

DF9001 is being evaluated in adult patients for the treatment of advanced solid EGFR-positive tumors. DF9001 has the potential to stimulate anti-tumor immunity in patients who are not eligible or not adequately responding to current therapies. DF9001 is the second wholly owned drug candidate in a pipeline of TriNKETs that Dragonfly is developing to address high unmet needs for patients across a broad range of disease areas..

DF9001正在成人患者中进行评估，以治疗晚期实体EGFR阳性肿瘤。DF9001有可能刺激不符合条件或对当前疗法反应不足的患者的抗肿瘤免疫力。DF9001是蜻蜓正在开发的一系列小饰品中的第二个全资候选药物，旨在解决广泛疾病领域患者的高度未满足需求。。

About Dragonfly

关于蜻蜓

Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing novel therapies that harness the body's immune system to bring breakthrough treatments to patients. In addition to a set of advanced programs in the clinic, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platforms that are progressing toward the clinic, as well as productive collaborations with AbbVie, Bristol Myers Squibb, Gilead and Merck in a broad range of disease areas..

蜻蜓疗法是一家临床阶段的生物制药公司，致力于发现、开发和商业化利用人体免疫系统为患者带来突破性治疗的新型疗法。除了临床上的一系列高级项目外，蜻蜓还拥有一大批全资临床前候选人，这些候选人是通过其专有平台发现的，这些平台正在朝着临床方向发展，并与艾伯维（AbbVie）、百时美施贵宝（Bristol-Myers Squibb）、吉利德（Gilead）和默克（Merck）在广泛的疾病领域进行了富有成效的合作。。